Trial result ·
Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This small pilot trial included people with Parkinson's disease or Lewy body dementia. It was randomised, double-blind and placebo-controlled. 12 people took part. It tested the diabetes drugs sitagliptin 100 mg and dapagliflozin 10 mg. Sitagliptin is a DPP4 inhibitor. Dapagliflozin is an SGLT2 inhibitor. Treatment lasted 4 weeks. The team looked at tolerability and early effects on movement scores, thinking and body-function markers.
What they found
Both drugs were well tolerated, with no adverse events. Thinking scores did not change significantly. The change in MDS-UPDRS scores differed across the groups. This was seen for part 1, part 2 and total scores. The p values were 0.008, 0.020 and 0.047. Trends in these scores were more favorable in the dapagliflozin group.
What it means for patients
They say this pilot suggests the drugs are safe in Parkinson's disease and DLB. They say the early findings give a basis for larger, longer studies. They say these would confirm possible symptom benefits and explore disease-modifying effects.
Why it is not certain yet
The study was small and short. All people had Parkinson's disease except one person with DLB. That person was in the DPP4 inhibitor group. The authors call the findings preliminary. A pilot study can only show early signals.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study.
PubMed · PMID 42318251We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Lewy body dementia publications